ESMO 2023

Remarkable efficacies in patients with HER2+ mBC with brain metastases

DATO-DX - where is it going?

5 year follow-up

Highlights in eBC

My highlights of ESMO23 in metastatic breast cancer

Preoperative checkpointinihition in ER+ disease

When the history of ADC is written: Redefining first-line standard of care in mUC!

New 3rd line therapy for RCC

Lu-PSMA leads forward

The FGFR story in bladder cancer at ESMO23

Early use of enzalutamide in advanced prostate cancer

Clearing up non-clear cell RCC

ALINA - immediate change of practice!

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

My highlights from ESMO 2023

Tarlatamab in SCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

What was the most exciting news at ESMO23?

Anticipated updates and exciting new data for checkpointinhibitors

New and better biomarkers are needed!

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What is your definition of triple-negative breast cancer?

Our guidelines are correct

MonarchE - trial update

Negative EFS results from NeoTrip

My highlights of ESMO23 in early breast cancer

Carry-over effects in monarchE confirmed

Pembrolizumab solidifies as SOC in early-stage TNBC

ER-low corresponds diagnostically to ER-0 breast cancer

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

5 year follow-up

Consolidation of data in early HR+ and triple-negative breast cancer

New data on neoadjuvant immunotherapy

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Ribociclib effective in all subtypes

Highlights in eBC

Analysis of tumour microenvironment and immunophenotype in TNBC

Preoperative checkpointinihition in ER+ disease

Immunoncology in eBC - triple negative and more?

HR+ study with > 20 % PCR

Clinically relevant effect of pembro also in PCR

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Detailed view of nodal-negative patients

MonarchE - mise à jour de l'essai

Punti salienti in eBC

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Nouvelles données sur l'immunothérapie néoadjuvante

Studio NeoTrip: negativi i risultati

Improvement of therapy outcome by app-based patient education

How to organize a molecular tumorboards in breast cancer?

What was the most exciting news at ESMO23?

New targets, new linker, new ADCs - much more to learn with new therapies!

New ADC for metastatic breast cancer?

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

TROP2 expression as a potential mechanism of resistance in HER2+ patients

T-DXd in HER2+ patients with brain metastases

HS20089 - a novel ADC is coming for TNBC

Fulvestran better than anastrozole, but no survival benefit

Still on track for success in HER2-low MBC

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Patient-centered molecular medicine - a new approach

HER2DX in the PHERgain trial

Benefit for SG even after intensive pretreatment

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Abemaciclib remains consistent in 5-year follow-up

Can surgery be spared following primary systemic therapy?

TULIP: Trastuzumab duocarmazine without OS benefit

ADC + Immunotherapy - the BEGONIA study paradigm

Even more new generation ADCs in breast cancer?

Our guidelines are correct

OP seems to be dispensable for super responders

New ADC in HR+ disease

Dato-DXd - new player in advanced luminal disease

T-DXd - new standard of care for brain mets?

DATO-DX - where is it going?

T-DXd also effective for brain metastases

Robust data from the monarchE

Highlights in mBC

Improved oncological therapy with the smartphone

Duvalumab + Dato-DXd effective

My highlights of ESMO23 in metastatic breast cancer

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

Lo studio BEGONIA nelle paziento con tumore triplo negativo

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Punti salienti in mBC

T-DXd - nowy standard postępowania w przerzutach do mózgu?

HER2DX en el estudio PHERgain

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

What is the future of immune therapy in prostate cancer?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust data is needed.

EMBARK expands ENZA indication to PCa

Negative data for pembrolizumab in mHSCPC & mCRPC

PSMAfore unleashes urooncologic opportunity

PSMA FORE: Trial and controversies

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

Lu-PSMA leads forward

Immunotherapy in metastatic PCa

Precision medicine at mCRCP

Longterm toxicity of adjuvant RT after prostatectomy

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Brave New World in mCRPC

EMBARK - Quality of Life

Big data and AI prediction tools

TITAN: ultra-low PSA = best prognosis

CXCR2 inhibitor in PCa

IO therapy in metastatic prostate cancer.

Osteoprotection at mHSPC

RADICALS RT: Trial and controversies

Early use of enzalutamide in advanced prostate cancer

Combination of radioligand therapy with chemotherapy useful

Embark without fear

ENZA P:Trial and controversies

Salvage radiotherapy the new standard

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

CXCR2 hämmare och prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Immunterapi vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

Part 2: New standard of care in first line urothelial cancer!

Part1: New standard of care in first line urothelial cancer?!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

When the history of ADC is written: Redefining first-line standard of care in mUC!

The FGFR story in bladder cancer at ESMO23

New SoC in firstline bladder cancer

Chemo-IO establishes itself in the first-line treatment of bladder cancer

Amazing new data in bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

EV + Pembro as standard of care in first-line therapy of bladder cancer

DAD, DAD-IO

Unique bladder delivery system of gemcitabine herolds remarkable response

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Where does the future therapy go in renal cell carcinoma?

Important new treatment option but only for subset of patients?

Is de-escalating therapy ready for prime-time?

Kidney cancer highlights at ESMO23

Belzutifan - whats next kidney cancer?

Intermittent therapy also possible with TKIs

New 3rd line therapy for RCC

Belzutifan in later lines of therapy

New mode of action in mRCC - ready for prime time?

Clearing up non-clear cell RCC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Circulating DNA in AEGEAN trial

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Big improvements in early stage and a subset of metatstic NSCLC

Scene is set for inductive immunotherapy

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

ALINA - immediate change of practice!

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Substantial improvement in local regional NSCLC

My highlights from ESMO 2023

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Les points forts de l'ESMO 2023

I miei punti salienti di ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Activating EGFR-mutation - what's coming up?

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

TROPION-Lung01: positive development

Big improvements in early stage and a subset of metatstic NSCLC

Brain metastases – options to improve the systemic treatment

LIBRETO - a positive study, but was it necessary?

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Adagrasib + pembrolizumab in patients with KRASG12C mutation

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Substantial improvement in rare alterations

NRG fusions: a new drugable target?

Treatment sequences for EGFR-mutated Patients

By unanimous decision and still the champion – docetaxel!

Does immunotherapy still have a place in EGFR-positive mNSCLC?

MARIPOSA II: Trial and controversies

My highlights from ESMO 2023

PAPILLON - bringing together therapy for the 1st line

Amivantamab upfront? MARIPOSA trial

Do ADCs have brain activity?

Changing treatment landscape in EGFR-mutated NSCLC

MARIPOSA: Trial and controversies

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Amivantamab at progression? MARIPOSA-2 trial

Practice changing results on exon 20 insertion mNSCLC

I miei punti salienti di ESMO 2023

Amivantamab at progression? MARIPOSA-2 trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Quelles séquences thérapeutiques pour les patients EGFR mutés

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Amivantamab upfront? MARIPOSA trial

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Les points forts de l'ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Impact of T-cell engagers in SCLC

New hope for patients with SCLC

Tarlatamab in SCLC

A new option in relapsed SCLC

Neue Hoffnung für Patienten mit SCLC

New data on H&N Cancer

Update on gynaecological cancers

Precision oncology in CUP

Evolution of the revolution - the RUBY trial

PCO Therapeutics

First data on luveltamab in multiline treatment for endometrial cancer

New data on sarkomas